New Opportunities in Cardiovascular Patient Management: A Survey of Clinical Data on the Combination of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers

American Journal of Cardiology

Volumn 100, Issue 3 SUPPL., 2007, Pages

  Weber, Michael A ^a  

^a SUNY Downstate Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; BRADYKININ; CANDESARTAN; CANDESARTAN HEXETIL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; IRBESARTAN; LISINOPRIL; LOSARTAN; NITRIC OXIDE; PLACEBO; PROSTACYCLIN; RAMIPRIL; TELMISARTAN; TRANDOLAPRIL; VALSARTAN;

ACUTE HEART INFARCTION; ARTICLE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG DOSE TITRATION; DRUG EFFECT; DRUG INHIBITION; DRUG RECEPTOR BINDING; DRUG SAFETY; ESSENTIAL HYPERTENSION; FOLLOW UP; HEALTH SURVEY; HEART FAILURE; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; KIDNEY DISEASE; META ANALYSIS; MONOTHERAPY; MORBIDITY; MORTALITY; PATIENT CARE; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STROKE; SURVIVAL RATE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; KIDNEY DISEASES; RANDOMIZED CONTROLLED TRIALS; RENIN-ANGIOTENSIN SYSTEM;

EID: 34547107088     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.05.014     Document Type: Article

References (45)

1. National Institutes of Health. National Heart, Lung, and Blood Institute. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda, MD: National Institutes of Health, National Heart, Lung, and Blood Institute; December 2003. NIH Publication No. 03-5233.
2. Lavoie J.L., and Sigmund C.D. Minireview: Overview of the renin-angiotensin system: an endocrine and paracrine system. Endocrinology 144 (2003) 2179-2183
3. Schmieder R.E. Mechanisms for the clinical benefits of angiotensin II receptor blockers. Am J Hypertens 18 (2005) 720-730
4. Luňo J., Praga M., and de Vinuesa S.G. The reno-protective effect of the dual blockade of the renin angiotensin system (RAS). Curr Pharm Des 11 (2005) 1291-1300
5. Azizi M., and Ménard J. Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation 109 (2004) 2492-2499
6. Huang X.R., Chen W.Y., Truong L.D., and Lan H.Y. Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol 14 (2003) 1738-1747
7. Wagenaar L.J., Voors A.A., Buikema H., and van Gilst W.H. Angiotensin receptors in the cardiovascular system. Can J Cardiol 18 (2002) 1331-1339
8. Yong-Sheng K.E., Yue-Yu T.A.O., Hao Y., and Guo-Hua Y.U. Effects of valsartan with or without benazepril on blood pressure, angiotensin II, and endoxin in patients with essential hypertension. Acta Pharmacol Sin 24 (2003) 337-341
9. Doulton T.W.R., He F.J., and MacGregor G.A. Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension 45 (2005) 880-886
10. Jacobsen P., Andersen S., Rossing K., Hansen B.V., and Parving H.H. Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy. Nephrol Dial Transplant 17 (2002) 1019-1024
11. Azizi M., Linhart A., Alexander J., Goldberg A., Menten J., Sweet C., and Menard J. Pilot study of combined blockade of the renin-angiotensin system in essential hypertensive patients. J Hypertens 18 (2000) 1139-1147
12. Stergiou G.S., Skeve I.I., Baibas N.M., Roussias L.G., Kalkana C.B., Achimastos A.D., and Mountokalakis T.D. Additive hypotensive effect of angiotensin-converting enzyme inhibition and angiotensin-receptor antagonism in essential hypertension. J Cardiovasc Pharmacol 5 (2000) 937-941
13. Agarwal R. Add-on angiotensin receptor blockade with maximized ACE inhibition. Kidney Int 59 (2001) 2282-2289
14. Ferrari P., Marti H.-P., Pfister M., and Frey F.J. Additive anti-proteinuric effect of combined ACE inhibition and angiotensin II receptor blockade. J Hypertens 20 (2002) 125-130
15. Rossing K., Christensen P.K., Jensen B.R., and Parving H.H. Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. Diabetes Care 25 (2002) 95-100
16. Jacobsen P., Andersen S., Rossing K., Jensen B.R., and Parving H. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int 63 (2003) 1874-1880
17. Jacobsen P., Andersen S., Jensen B.R., and Parving H.-H. Additive effect of ACE inhibition and angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. J Am Soc Nephrol 14 (2003) 992-999
18. Rossing K., Jacobsen P., Pietraszek L., and Parving H.H. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. Diabetes Care 26 (2003) 2268-2274
19. Morgan T., Anderson A., Bertram D., and MacInnis R.J. Effect of candesartan alone and in combination on blood pressure and microalbuminuria. J Renin Angiotensin Aldosterone Syst 5 (2004) 64-71
20. Mogensen C.E., Neldam S., Tikkanen I., Oren S., Viskoper R., Watts R.W., Cooper M.E., and CALM Study group. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the Candesartan and Lisinopril Microalbuminuria (CALM) study. BMJ 321 (2000) 1440-1444
21. Berger E.D., Bader B.D., Ebert C., Risler T., and Erley C.M. Reduction of proteinuria; combined effects of receptor blockade and low dose angiotensin-converting enzyme inhibition. J Hypertens 20 (2002) 739-743
22. Nakao N., Yoshimura A., Morita H., Takada M., Kayano T., and Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 361 (2003) 117-124
23. Weir M.R., Smith D.H.G., Neutel J.M., and Bedigian M.P. Valsartan alone or with a diuretic or ACE inhibitor as treatment for African American hypertensives: relation to salt intake. Am J Hypertens 14 (2001) 665-671
24. Izzo J.L., Weinberg M.S., Hainer J.W., Kerkering J., Tou C.K.P., and AMAZE. Antihypertensive efficacy of candesartan-lisinopril in combination vs. up-titration of lisinopril: the AMAZE trials. J Clin Hypertens (Greenwich) 6 (2004) 485-493
25. Andersen N.H., Poulsen P.L., Knudsen S.T., Poulsen S.H., Eiskjær H., Hansen K.W., Helleberg K., and Mogensen C.E. Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II Study. Diabetes Care 28 (2005) 273-277
26. Codreanu I., Perico N., and Remuzzi G. Dual blockade of the renin-angiotensin system: the ultimate treatment for renal protection?. J Am Soc Nephrol 16 suppl1 (2005) S34-S38
27. Wolf G., and Ziyadeh F.N. Renal tubular hypertrophy induced by angiotensin II. Semin Nephrol 17 (1997) 448-454
28. Kincaid-Smith P., Fairley K.F., and Packham D. Dual blockade of the renin-angiotensin system compared with a 50% increase in the dose of angiotensin-converting enzyme inhibitor: effects on proteinuria and blood pressure. Nephrol Dial Transplant 19 (2004) 2272-2274
29. Song J.H., Cha S.H., Hong S.B., and Kim D.H. Dual blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chronic kidney disease. J Hypertens Suppl 24 (2006) S101-S106
30. Wade V.L., and Gleason B.L. Dual blockade of the renin-angiotensin system in diabetic nephropathy. Ann Pharmacother 38 (2004) 1278-1282
31. Sengul A.M., Altuntas Y., Kürklü A., and Aydin L. Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension. Diabetes Res Clin Pract 71 (2006) 210-219
32. McMurray J.J., Östergren J., Swedberg K., Granger C.B., Held P., Michelson E.L., Olofsson B., Yusuf S., Pfeffer M.A., and CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362 (2003) 767-771
33. McMurray J.J.V., Young J.B., Dunlap M.E., Granger C., Hainer J., Michelson E., Earle S., Olofsson B., Östergren J., Yusuf S., and CHARM Investigators. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. Am Heart J 151 (2006) 985-991
34. Cohn J.N., Tognoni G., and Valsartan Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 (2001) 1667-1675
35. Krum H., Carson P., Farsang C., Maggioni A.P., Glazer R.D., Aknay N., Chiang Y.T., and Cohn J.N. Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT. Eur J Heart Fail 6 (2004) 937-945
36. Pfeffer M.A., McMurray J.J., Velazquez E.J., Rouleau J.L., Kober L., Maggioni A.P., Solomon S.D., Swedberg K., Van de Werf F., White H., et al., Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349 (2003) 1893-1906
37. Kasama S., Toyama T., Kumakura H., Takayama Y., Ichikawa S., Suzuki T., and Kurabayashi M. Addition of valsartan to an angiotensin-converting enzyme inhibitor improves cardiac sympathetic nerve activity and left ventricular function in patients with congestive heart failure. J Nucl Med 44 (2003) 884-890
38. Petrovic J., Petrovic D., Vukovic N., Zinanovic B., Dragicevic J., Vasiljevic Z., and Babic R. Ventricular and vascular remodeling-effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients. J Int Med Res 33 suppl 1 (2005) 39A-49A
39. Suzuki H., Kanno Y., Kaneko K., Kaneko M., Kotaki S., Mimura T., and Takane H. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy. Ther Apher Dial 8 (2004) 320-327
40. Cice G., di Benedetto A., D'Isa S., D'Andrea A., De Gregorio P., and Calabro R. Effect of telmisartan added to angiotensin converting enzyme inhibitors in reducing morbidity and mortality in haemodialysis patients with chronic heart failure [abstract]. Nephrol Dial Transplant 20 suppl 5 (2005) 187
41. Burnier M., and Brunner H.R. Angiotensin II receptor antagonists. Lancet 19 (2000) 637-645
42. Galzerano D., Tammaro P., Cerciello A., Breglio R., Mallardo M., Lama D., Tuccillo B., and Capogrosso P. Freehand three-dimensional echocardiographic evaluation of the effect of telmisartan compared with hydrochlorothiazide on left ventricular mass in hypertensive patients with mild-to-moderate hypertension: a multicentre study. J Hum Hypertens 18 (2004) 53-59
43. Barnett A.H., Bain S.C., Bouter P., Karlberg B., Madsbad S., Jervell J., Mustonen J., and Diabetics Exposed to Telmisartan and Enalapril Study Group. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Eng J Med 351 (2004) 1952-1961
44. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G., and Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342 (2000) 145-153
45. Sleight P. The ONTARGET/TRANSCEND trial program: baseline data. Acta Diabetol 42 suppl 1 (2005) S50-S56